Genomics Market Report 2025

This Genomics market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The genomics market size has grown rapidly in recent years. It will grow from $45.47 billion in 2024 to $53.92 billion in 2025 at a compound annual growth rate (CAGR) of 18.6%. The growth in the historic period can be attributed to reduction in sequencing costs, research and discovery, healthcare applications, personalized medicine.

The genomics market size is expected to see exponential growth in the next few years. It will grow to $112.78 billion in 2029 at a compound annual growth rate (CAGR) of 20.3%. The growth in the forecast period can be attributed to growing awareness and education, drug development and therapeutics, diagnostic applications, regulatory and ethical frameworks. Major trends in the forecast period include technological advancements, genomic sequencing in agriculture, collaboration and partnerships, genomic data analytics.

Increased government investment in genomics research has been a catalyst for the expansion of the single-cell genomics market. Government funds are dedicated to unraveling the complexities of the human genome, understanding the genomic foundations of human health and ailments, and ensuring the safe and beneficial utilization of genomics in patient care. For example, in December 2022, GOV.UK, a UK-based government services and information provider, reported that the UK government allocated £175 million ($229.83 million) in 2022 to enhance genomic healthcare. This funding focuses on innovative technologies aimed at improving the diagnosis and treatment of various diseases, including cancer and rare genetic disorders. These initiatives aim to fortify genomic sequencing infrastructure, disbursed across three distinct phases.

The anticipated rise in genetic disorder occurrences is expected to act as a driving force behind the growth of the genomics market. Genetic disorders, stemming from irregularities in an individual's DNA, manifest in various physical or mental abnormalities, diseases, or predisposition to certain health conditions, commonly inherited from parents. Genomics plays a pivotal role in enabling precise diagnosis, personalized treatments, and risk evaluation for genetic disorders by examining an individual's genetic data. For instance, in October 2022, according to the Implementation Plan for England, the Test Directory includes 357 clinical indications for rare diseases, covering approximately 3,200 rare and inherited diseases, as well as 203 clinical indications for cancer. This directory supports the NHS Genomic Medicine Service (GMS) in performing over 680,000 genomic tests annually in England for common and rare inherited diseases, pharmacogenomics, and cancer. Consequently, the rising prevalence of genetic disorders is driving growth in the genomics market.

Major companies in the genomics market are increasingly focused on technological advancements, such as long read technology, to improve genome sequencing accuracy, enable the analysis of larger and more complex genetic regions, and offer deeper insights into genetic variations that were previously challenging to detect. Long read technology involves sequencing longer DNA or RNA segments, allowing for more precise and comprehensive genetic analysis, and facilitating the detection of complex variations and disease-related markers. For example, in March 2023, Illumina Inc., a US-based biotechnology company, launched Illumina's Complete Long Read Prep. This solution offers an efficient, low-input approach for whole-genome sequencing, delivering both long- and short-read data on the same device with simplified workflows and requiring fewer materials compared to other technologies.

Prominent players within the genomics sector are actively engaged in the development of groundbreaking personalized medicine solutions. Personalized medicine is a paradigm shift that enables healthcare practitioners to tailor medical interventions precisely to individual patient needs. This approach not only ensures superior care outcomes but also heralds the potential to supplant conventional pharmaceuticals and surgical procedures through the emerging field of gene therapy. For example, in May 2022, Illumina, a leading US-based biotechnology company, entered into a strategic partnership with Janssen, a pharmaceutical company based in Belgium. This collaboration aims to expedite the advancement of precision medicines, harnessing Illumina's extensive resource portfolio, encompassing data analytics tools, early discovery research, companion diagnostics, and commercialization solutions. The alliance also seeks to streamline collaboration with pharmaceutical partners in various aspects, from novel drug target discovery to early screening, therapy selection, and monitoring.

In July 2024, Petrosys Pty Ltd, an Australia-based software company, acquired Talus Technologies Inc. for an undisclosed amount. Through this acquisition, Petrosys aims to enhance its portfolio of advanced software solutions for the energy and resource industries, with a particular focus on improving data visualization. Talus Technologies Inc., a Canada-based company, specializes in the discovery and development of therapeutics targeting transcription factors (TFs).

Genomics is the study of an organism's entire set of genes (genome), focusing on their structure, function, evolution, and mapping. It involves analyzing the sequencing and interactions of DNA, RNA, and proteins to understand how genes regulate biological processes and influence traits and diseases. Genomics is pivotal in fields such as medicine, agriculture, and biotechnology, driving advancements in personalized medicine, enhancing crop yields, and enabling the development of targeted therapies for genetic disorders.

The primary product types within genomics include instruments (comprising systems, service contracts, and software) and reagents (consisting of reagents and consumables). Reagents are substances or compounds added to a system to initiate a chemical reaction or to assess whether a reaction has occurred. Different processes within genomics encompass cell isolation, sample preparation, and genomic analysis, and these processes are employed by academic institutions, biopharmaceutical companies, and clinical research institutes.

The genomics market research report is one of a series of new reports that provides genomics market statistics, including genomics industry global market size, regional shares, competitors with a genomics market share, detailed genomics market segments, market trends and opportunities, and any further data you may need to thrive in the genomics industry. This genomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Major companies operating in the genomics market include 10X Genomics Inc., Qiagen NV, Standard BioTools Inc., Johnson and Johnson, Illumina Inc., Affymetrix Inc., Angle PLC, Denovo Sciences Inc., Diagnologix LLC, DNA Electronics Ltd., Epic Sciences, Kellbenx Inc., Resolution Bioscience Inc., Wafergen Bio-systems Inc., Yikon Genomics Co. Ltd., Thermo Fisher Scientific Inc., Beckman Coulter Inc., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Carl Zeiss Microscopy GmbH, Cell Microsystems Inc., CellSorter, CYTENA GmbH, Dolomite Bio Limited, Agilent Technologies Inc., Fluxion Biosciences Inc., BGI Group, F. Hoffmann-La Roche AG, Oxford Nanopore Technologies Ltd., Pacific Biosciences of California Inc., Eurofins Scientific SE, Danaher Corporation, PerkinElmer Inc.

North America was the largest region in the genomics market in 2024. Western Europe was the second largest region in the genomics market. The regions covered in the genomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The genomics market consists of sales of genomics such as structural genomes, functional genomes, mutation genomics and comparative genomics that are used for drug discovery and development. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.